Benefits
Metabolic Health and Weight Management
OEA is a satiety and metabolic signaling molecule; Trpti's bioavailable form supports metabolic and weight management applications.
Gut Microbiome Modulation
Saanroo 2026 published trial in Gut Microbes Reports demonstrated targeted modulation of gut microbiome with Trpti.
Intestinal Barrier Function
Same trial showed improvements in intestinal barrier function — relevant to gut health and metabolic health (gut-derived inflammation contributes to metabolic dysfunction).
Inflammatory Signaling Modulation
Effects on inflammatory pathways relevant to metabolic and digestive applications.
Satiety Support
OEA's role in satiety signaling supports appetite regulation.
Mechanism of action
OEA Endogenous Satiety Signaling
OEA is produced by intestinal cells in response to dietary fat; binds PPAR-alpha receptors; signals satiety to brain via vagal nerve. Endogenous appetite regulation pathway.
PPAR-alpha Activation
OEA activates PPAR-alpha — nuclear receptor regulating fatty acid metabolism, lipogenesis, satiety.
Gut Microbiome Effects
OEA modulates gut microbiome composition supporting beneficial bacterial populations.
Intestinal Barrier Support
Supports gut barrier integrity — relevant to gut-derived inflammation and metabolic dysfunction.
Clinical trials
Human clinical trial of Trpti bioavailable OEA in overweight adults; published Gut Microbes Reports March 2026.
Overweight adults.
Targeted modulation of gut microbiome; assessments of intestinal barrier function and inflammatory signaling. Established Trpti's gut and metabolic effects.
About this ingredient
TRPTI is a BIOAVAILABLE FORM OF OLEOYLETHANOLAMIDE (OEA) developed by SAANROO (formerly Gencor Pacific). OEA is an ENDOGENOUS LIPID MEDIATOR (similar fatty acid amide family as PEA - palmitoylethanolamide / Levagen): produced by INTESTINAL CELLS in response to dietary fat consumption; signals SATIETY to the brain via vagal nerve; modulates lipid metabolism via PPAR-alpha. Trpti is bioavailable form of this naturally-occurring molecule.
EVIDENCE-BASED USES: (1) Metabolic health and weight management; (2) Gut microbiome modulation (2026 published trial); (3) Intestinal barrier function support; (4) Satiety signaling support; (5) Inflammatory signaling modulation.
CRITICAL CAUTIONS: (1) NEW INGREDIENT — relatively recent commercial introduction (2026 published trial); long-term safety data developing; (2) DOSE — per Saanroo specification; (3) METABOLIC HEALTH FRAMEWORK — comprehensive approach foundational; Trpti one tool; (4) OEA vs PEA — both fatty acid amides; OEA primarily metabolic/satiety; PEA primarily anti-inflammatory/pain; complementary mechanisms; (5) GUT MICROBIOME RESEARCH — emerging field; targeted modulation evidence interesting; clinical translation developing; (6) BIOAVAILABILITY — endogenous OEA is unstable; bioavailable form addresses delivery challenge; (7) For COMPREHENSIVE METABOLIC HEALTH — diet, exercise, weight management foundational; Trpti provides emerging mechanism support; (8) SATIETY APPROACHES — Trpti complements appetite-control approaches (Slimaluma, Caralluma, glucomannan); different mechanism (endogenous signaling vs physical bulk); (9) INFLAMMATORY METABOLIC SYNDROME — gut-derived inflammation drives metabolic dysfunction; Trpti's gut barrier and microbiome effects relevant; (10) Recent commercial introduction; ongoing clinical research.